Development of PET radiotracers for proteinopathy neuroimaging has historically focused on a handful of biological targets, namely protein aggregates of amyloid-beta, hyperphosphorylated tau, and alpha-synuclein12–16. The gene discussed is MAPT; the disease is proteostasis deficiencies.